Skip to main
ARDX

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx is in a strong financial position with significant milestones in their pipeline, including ongoing Phase 3 trials for Ibsrela and Xphozah, and a successful patient assistance program. With a patent in place until 2042, the company has a stable foundation for long-term growth and expansion opportunities in the treatment of CIC and other conditions. As they continue to progress in their clinical trials and expand their market reach, Ardelyx has the potential for sustained revenue growth and higher shareholder value.

Bears say

Ardelyx is facing challenges with its increasing operating expenses, low adherence to Xphozah due to high pill burden, and potential competition in the CIC market, which could impact the company's top-line growth and future adoption of its products. The company must successfully execute the ongoing Phase 3 ACCEL trial and demonstrate meaningful benefits for CIC patients to maintain growth as per its revenue guidance targets. Additionally, the company must differentiate its NHE3 inhibitor IBSRELA from other approved secretagogues in the market and gain broader labeling and familiarity among prescribers to ensure future adoption and treatment of both IBS-C and CIC patients.

Ardelyx (ARDX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Ardelyx (ARDX) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.